so, we partnered with some AI company to come up with other indications?
We now gathered HIV patients to convince the FDA that this drug is worth the effort (why would the FDA need this? it is cytodyn's problem if nobody buy the drug - the FDA is just approving it.)
Based on these testimonials, we can tell the fda only one application for a specific HIV group that Leronlimab is good for the most so they can consider lifting a hold based on non-existent safety issue?
They need to authorize more shares. How about taking the amarex cash and buying back the shares that were authorized to pay them?
We need to do a pre-trial for NASH before we get a partnership.
sounds to me like we should file a BLA for HIV as we are spending so much time and money convincing the FDA there are HIV positive people that have a huge problem with side effects and drug resistance. (apparently the FDA is unaware)
All other indications are years away at this pace, the only near term catalyst is getting the hold lifted and getting something out of Amarex. The good news is that they did state that they are seeking damages from Amarex and its parent company NSF.
We now gathered HIV patients to convince the FDA that this drug is worth the effort (why would the FDA need this? it is cytodyn's problem if nobody buy the drug - the FDA is just approving it.)
Based on these testimonials, we can tell the fda only one application for a specific HIV group that Leronlimab is good for the most so they can consider lifting a hold based on non-existent safety issue?
They need to authorize more shares. How about taking the amarex cash and buying back the shares that were authorized to pay them?
We need to do a pre-trial for NASH before we get a partnership.
sounds to me like we should file a BLA for HIV as we are spending so much time and money convincing the FDA there are HIV positive people that have a huge problem with side effects and drug resistance. (apparently the FDA is unaware)
All other indications are years away at this pace, the only near term catalyst is getting the hold lifted and getting something out of Amarex. The good news is that they did state that they are seeking damages from Amarex and its parent company NSF.
4
